Virus-like Particle Vaccines of Infectious Bursal Disease Virus Expressed in <i>Escherichia coli</i> Are Highly Immunogenic and Protect against Virulent Strain.

Abstract

<h4>Objectives</h4>Infectious bursal disease virus (IBDV) is a highly contagious, acutely infectious agent that causes immunosuppression in chickens. We expressed IBDV VP2 proteins in <i>Escherichia coli</i> (<i>E. coli</i>) to develop an effective virus-like-particles (VLPs) vaccine and evaluated its immunogenicity.<h4>Methods</h4>The VLPs produced in <i>E. coli</i> were used as an immunogen mixed with a water-in-mineral-oil adjuvant (Montanide^TM ISA 71 VG, ISA 71 RVG) or a white oil (7#) adjuvant. VLPs without an adjuvant, commercial subunit vaccine, inactivated vaccine, and attenuated vaccine were used as controls. These test vaccines were intramuscularly injected into 19-day-old SPF chickens, which were challenged with the IBDV virulent strain at 30 days after vaccination.<h4>Results</h4>The adjuvants boosted antibody production, and the adjuvant groups (except white oil) produced higher antibody levels than the non-adjuvanted controls and the commercial vaccine groups. In terms of cellular immunity, the VLPs plus adjuvant combinations produced higher levels of cytokines, IL-2, IL-4, and IFN-γ than the controls.<h4>Conclusion</h4>IBDV VLPs plus the ISA 71 RVG adjuvant can be used as an optimal vaccine combination for improving the immune efficacy of IBD subunit vaccines, which can protect against the virulent strain.